Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London

Hansa Biopharma reported positive five-year follow-up data from its 17-HMedIdeS-14 extended pooled analysis for imlifidase-enabled kidney transplants in highly sensitized patients. The study demonstrated sustained positive outcomes, with a 90% patient survival rate and 82% graft survival (death censored) at five years, alongside a mean eGFR of 50 mL/min/m2, consistent with three-year results. This confirms imlifidase as a viable and long-term option for HLA-incompatible transplantation, offering a critical alternative to dialysis for patients with limited transplant access.

Analysis

Hansa Biopharma has presented compelling five-year follow-up data from its 17-HMedIdeS-14 pooled analysis for imlifidase in highly sensitized kidney transplant patients. The results demonstrate sustained, long-term efficacy, with a patient survival rate of 90% and a death-censored graft survival rate of 82% at the five-year mark, figures that are consistent with previous three-year outcomes. Critically, mean kidney function (eGFR) was reported at 50 mL/min/m2, a level that compares favorably to the 40-60 ml/min range typically observed in standard transplant recipients at three years, a cohort where function often continues to decline by year five. This data substantiates imlifidase's role as a viable desensitization therapy, enabling life-saving transplants for a difficult-to-treat patient population that would otherwise remain on dialysis. These positive long-term results are pivotal for Hansa Biopharma as it continues to build its clinical evidence base to support the drug's conditional marketing approval and future commercial expansion.

Key Decisions for Investors

• The sustained five-year efficacy and survival data significantly de-risks the long-term clinical profile of imlifidase, strengthening the fundamental investment case for Hansa Biopharma.
• Investors should now shift focus to the company's commercial execution, monitoring sales ramp-up and market penetration, as these strong outcomes provide a compelling case for broader adoption and reimbursement.
• Upcoming regulatory catalysts, particularly data from the US-based ConfIdeS trial and progress towards full marketing authorization in Europe, should be monitored as the next major potential value-inflection points.